2013至2019年法国出生儿童百日咳疫苗效果评估
本研究采用匹配病例对照设计,利用法国国家健康数据系统评估2013至2019年出生儿童接种百日咳疫苗的效果。共纳入1,481,884名儿童,按1、2、3剂有效剂量计算比值比并估算疫苗效果(VE)。结果显示,按2+1程序完全接种的11.5至60月龄儿童VE最高(93.4%),仅接种首剂的2至4.5月龄儿童VE最低(24.1%)。
要点
- 按2+1程序完全接种的11.5至60月龄儿童疫苗效果达93.4%。
- 仅接种首剂的2至4.5月龄儿童疫苗效果为24.1%。
- 研究支持法国2013年修订的2+1接种程序对足月儿童有效。
核心结论
- 在法国足月儿童中,遵循2+1接种程序可提供有效的百日咳保护。
研究设计与样本
- 匹配病例对照研究,使用法国国家健康数据系统,纳入2013至2019年出生、6周龄时存活且无百日咳、母子链接可用的儿童,共1,481,884名。
主要发现
- 按年龄分层,疫苗效果随剂次增加呈梯度上升,11.5至60月龄按2+1程序完全接种者VE最高(93.4%),2至4.5月龄仅接种首剂者VE最低(24.1%)。
- 敏感性分析中,对可能通过母婴保护机构在医保体系外接种的缺失数据进行插补后,VE约增加6%。
关键数值与推荐
- 疫苗暴露通过ATCC代码(J07CA02、J07CA06、J07CA09)确认,百日咳住院通过ICD-10代码(A37.0和A37.9)捕获。
- 疫苗效果(VE)按(1-调整OR)×100%在足月婴儿中估算,OR通过条件logistic回归模型计算。
临床怎么用
- 临床与公共卫生应继续推荐和落实2+1百日咳疫苗接种程序,以维持对足月儿童的有效保护。
局限性
- 研究仅针对足月儿童,未报告早产儿等其他人群的疫苗效果。
- 原文提及2013年后法国儿童疫苗效果数据有限,且可能遗漏医保体系外接种记录。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although effective pertussis vaccines are available and have been incorporated into national immunization programs for infants and children, and adolescents and adults in some countries, pertussis remains endemic worldwide. Periodic outbreaks occur every 2 to 5 years. In 2013, France revised its pediatric vaccination program, transitioning from a 3 + 1 to a 2 + 1 schedule. The effects of this change have raised some concerns; however, data on the effectiveness of pediatric vaccines in France post 2013 remain limited. This matched case-control study aimed to estimate the effectiveness of vaccination against pertussis in children born in France between 2013 and 2019, using the French National Health Data System. Children were included in the study if they were alive and free of pertussis at 6 weeks of age, and if their mother-child linkage was available. Pertussis-related hospitalizations were captured using the International Classification of Diseases-10 codes (A37.0 and A37.9), and vaccine exposure status was confirmed using ATCC codes (J07CA02, J07CA06, and J07CA09). The odds ratio (OR) of exposure to vaccine against pertussis for 1, 2, and 3 effective doses was calculated using conditional logistic regression models. Vaccine effectiveness (VE) was estimated as (1-adjusted OR) × 100% in at-term infants. In total, 1,481,884 children were included in the study. When stratified by age groups, a gradient of increasing VE was observed, with highest VE (93.4%) observed among children aged 11.5 to 60 months who were fully vaccinated according to 2 + 1 schedule and lowest (24.1%) among children aged 2 to 4.5 months who received only the first dose. In sensitivity analyses, imputation of missing data on vaccinations potentially received outside the healthcare insurance setting (Protection maternelle et infantile) resulted in an approximately 6% increase in VE. Results demonstrated that adherence to the 2 + 1 schedule provided effective protection against pertussis in full term children in France.
引用
- Vargas-Zambrano JC, Arnaud M, Antunes A, et al. Evaluating pertussis vaccine effectiveness in children under 5 years of age born in France between 2013 and 2019. Vaccine. 2026. PMID: 41880820. doi:10.1016/j.vaccine.2026.128472
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。